CurveBeam AI balances softer receipts with new orders and progress on regulatory and robotic-surgery fronts

Curvebeam AI Ltd. ( (AU:CVB) ) has issued an announcement.

CurveBeam AI reported five device purchase orders in the March quarter, matching the prior period, with sales spread across the U.S., Europe and China, and four of the units being its flagship HiRise system. Customer receipts fell to A$1.4 million, below both the prior year and prior quarter, although the company carried A$5.4 million of purchase orders and receivables into the June quarter, reflecting a revenue cycle that can take up to six months from order to full payment.

Regulatory and strategic initiatives advanced, with the company responding to FDA feedback on its bone mineral density module for multidetector CT scanners and targeting clearance in the second half of calendar 2026. CurveBeam AI also progressed Chinese approval for HiRise, which would enable sales and milestone payments with partner WEGO Orthopaedics, and deepened collaborations with leading robotic surgery system vendors to validate HiRise compatibility and develop new total hip arthroplasty protocols, broadening its role in the robotic and patient-specific instrumentation ecosystem.

The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.

More about Curvebeam AI Ltd.

CurveBeam AI Ltd., listed on the ASX as CVB, develops point-of-care specialised CT imaging equipment and AI-enabled SaaS clinical assessment solutions for orthopaedic and related applications. The company’s product portfolio includes the HiRise and PedCat systems, with a growing focus on integration into robotic surgery ecosystems and expansion into key markets such as the U.S., Europe and China.

Average Trading Volume: 603,628

Technical Sentiment Signal: Sell

Current Market Cap: A$27.23M

See more insights into CVB stock on TipRanks’ Stock Analysis page.